Literature DB >> 1449848

Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.

S S Pedersen1.   

Abstract

Progressive pulmonary insufficiency is the major cause of morbidity and mortality in patients with the inherited disease cystic fibrosis. The basic defect involves a disturbed ion transport across cells, but it is not known how this leads to the airways becoming highly susceptible to recurrent respiratory tract infection with S. aureus, H. influenzae and P. aeruginosa as the dominating pathogens. P. aeruginosa is not a primary pathogen in CF and some degree of lung damage generally has taken place before colonization begins at approximately 10 years of age. Cross-infection occurs and the incidence of P. aeruginosa infection can be reduced by interrupting person-to-person spread. P. aeruginosa infection is a chronic infection that is never permanently eradicated. However, intensive antipseudomonal chemotherapy has contributed to improved survival rates. 90% of patients remain alive more than 10 years after onset of chronic P. aeruginosa and, on an average, they can maintain an almost unchanged lung function during that period. Diagnosis of chronic infection rests on bacteriological examination and demonstration of a specific antibody response. Immunological assays to detect an early antibody response were developed. It is characteristic, but not specific for CF, that chronic lung infection is caused by alginate producing mucoid P. aeruginosa. Alginate biosynthesis is under complex genetic control and possibly regulated by environmental factors. Alginate was purified from mucoid P. aeruginosa and characterized and it was shown to be immunologically heterogenous. It is generally assumed that the infection begins with strains that are nonmucoid, but serological analysis show that these strains probably also produce the mucoid substance, alginate, in vivo. Patients infected with mucoid strains demonstrate a significantly higher antibody response to all P. aeruginosa antigens and have a lower lung function when compared to patients infected with nonmucoid strains. Despite the pronounced humoral antibody response efficient immune clearance of P. aeruginosa does not occur. Mucoid P. aeruginosa are organisms that are deficient in most of the classical virulence factors. In vivo it grows in a protected biofilm as mucoid microcolonies, where bacteria are enmeshed in a loosely bound, highly hydrated extracellular matrix of alginate. Purified alginate was shown to inhibit chemotaxis of neutrophil leukocytes and unable to activate complement. A deficient SIgA antibody response to alginate has been observed in bronchial secretions and it was hypothesized to be associated with the epithelial transport defect.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449848

Source DB:  PubMed          Journal:  APMIS Suppl        ISSN: 0903-465X


  58 in total

1.  Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE).

Authors:  H Yu; J C Boucher; N S Hibler; V Deretic
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.

Authors:  Hirotoshi Matsui; Victoria E Wagner; David B Hill; Ute E Schwab; Troy D Rogers; Brian Button; Russell M Taylor; Richard Superfine; Michael Rubinstein; Barbara H Iglewski; Richard C Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Role of an alginate lyase for alginate transport in mucoid Pseudomonas aeruginosa.

Authors:  Sumita Jain; Dennis E Ohman
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Epimerase active domain of Pseudomonas aeruginosa AlgG, a protein that contains a right-handed beta-helix.

Authors:  Stephanie A Douthit; Mensur Dlakic; Dennis E Ohman; Michael J Franklin
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

6.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa.

Authors:  Aaron M Firoved; Vojo Deretic
Journal:  J Bacteriol       Date:  2003-02       Impact factor: 3.490

Review 8.  Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.

Authors:  Elio Rossi; Ruggero La Rosa; Jennifer A Bartell; Rasmus L Marvig; Janus A J Haagensen; Lea M Sommer; Søren Molin; Helle Krogh Johansen
Journal:  Nat Rev Microbiol       Date:  2020-11-19       Impact factor: 60.633

9.  Microarray analysis reveals induction of lipoprotein genes in mucoid Pseudomonas aeruginosa: implications for inflammation in cystic fibrosis.

Authors:  Aaron M Firoved; Wojciech Ornatowski; Vojo Deretic
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

10.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.